MammaPrint FFPE NGS Kit
K210973 is the FDA 510(k) clearance record for MammaPrint FFPE NGS Kit, a class II device, cleared for Agendia, Inc. on under FDA product code NYI (Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer). FDA's definition for product code NYI reads: "A device which uses a gene expression profile of a breast cancer tumor, from patients stage i or stage ii lymph node negative, with a tumor size of <5.0 cm, to provide a risk assessment for distant recurrence of breast cancer. The result...". FDA records list 8 510(k) clearances for Agendia, Inc., from to . As of , FDA records show no recalls naming K210973.
Clearance record
- Decision date
- Received
- (526 days to decision)
- Product code
- NYI Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer
- Regulation
- 21 CFR 866.6040
- Device class
- Class II
- Review panel
- Immunology
- Applicant
- Agendia, Inc. 22 Morgan, Irvina CA
- 510(k) summary
- Summary PDF
- Third party review
- No
Clearances, product code NYI
Trailing 12 monthsFDA records hold no clearances under product code NYI in the trailing twelve months.
Show the numbers
| Month | Clearances |
|---|---|
| November 2025 | 0 |
| December 2025 | 0 |
| January 2026 | 0 |
| February 2026 | 0 |
| March 2026 | 0 |
| April 2026 | 0 |
| May 2026 | 0 |
| June 2026 | 0 |
| July 2026 | 0 |
| August 2026 | 0 |
| September 2026 | 0 |
| October 2026 | 0 |
FIRST ARTICLE / WEEKLY
What cleared, what was recalled, and what changed in the standards. One edition a week for the people who make medical devices.
